Filter
333
Text search:
National
Pharmacovigilance
Policy
Featured
38
114
Language
Document type
186
53
40
20
18
6
5
4
1
Countries / Regions
18
14
13
13
12
11
11
11
9
9
8
8
7
6
6
5
5
4
4
4
4
4
4
3
3
3
3
3
3
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
Authors & Publishers
Publication Years
Category
164
44
11
6
6
4
1
Toolboxes
44
37
28
22
16
13
4
3
2
2
2
1
1
1
1
1
World Journal of Pharmaceutical and Medical Research vol. 5 (2019) 3, 129-132
Drug registration in Kenya started in 1982; the process mainly involves an evaluation committee at the Kenya Pharmacy and Poisons Board (PPB) that aims to approve products based on quality, safety and efficacy.
Framework for implementation.
The END TB Strategy.
22 December 2020
The COVID-19 vaccine safety guidance manual has been developed upon recommendation and guidance of GACVS members, as well as by experts incorporating current and available information critical to all stakeholders when COVID-19 vaccines will be introduced.
For ease of use, the man
...
This Pharmaceutical Country Profile for Kenya (2010) has been developed by the Ministry of Medical Services with support of the World Health Organization. The Profile contains information on existing socio-economic and health-related conditions, resources, regulatory structures and processes and out
...
The WHO Pharmaceuticals Newsletter provides you with the latest information on the safety of medicinal products and regulatory actions taken by authorities around the world.
In addition, this edition includes summary and recommendations from the virtual meeting of the members of the WHO Programme f
...
English version - This handbook sets out a the new paradigm for pharmacy practice. Its aim is to guide pharmacy educators in pharmacy practice, to educate pharmacy students and to guide pharmacists in practice to update their skills. The handbook, which brings together practical tools and knowledge,
...
DR-TB drugs under the microscope: Sources and prices for drug-resistant tuberculosis medicines
recommended
4th edition.
This report – now in its fourth edition – analyses the barriers and factors affecting access to treatment regimens for drug-resistant tuberculosis (DR-TB), including new and repurposed drugs. We provide detailed pricing profiles of key DR-TB drugs, using manufacturer responses to s
...
Master of Science in Pharmaceutical Management Dissertation
Second Generation, WHO Country Cooperation Strategy, 2010–2015, Namibia
Towards ending tuberculosis and multidrug-resistant tuberculosis.
